UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant [ X ]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only
(as permitted by Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[ X ] Definitive Additional Materials
[ ] Soliciting Material under Rule 14a-12
OraSure Technologies, Inc.
--------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
--------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[ X ] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
the filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registrant
statement number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
<PAGE>
[EPITOPE LOGO]
September 11, 2000
To: Stockholders of Epitope and STC Technologies
Subject: Joint Proxy Statement/Prospectus - OraSure Technologies, Inc.
Dear Stockholder:
You should have recently received a copy of the joint proxy statement/prospectus
for OraSure Technologies, the company that would result from the merger of
Epitope and STC Technologies.
--------------------------------------------------------------------------------
THE TOLL-FREE NUMBER LISTED IN THE DOCUMENT HAS AN ERROR AND SHOULD READ:
800-628-8509
--------------------------------------------------------------------------------
You can call this number if you have questions on material in the proxy
statement/prospectus, or if you want to know the number of shares that will be
provided to STC Technologies stockholders. The number of shares will not be
known with certainty until the 20 trading day period defined in the Agreement
and Plan of Merger. This period will end with the close of trading on September
25, 2000.
--------------------------------------------------------------------------------
YOUR VOTE IS IMPORTANT. IF YOU DO NOT EITHER VOTE YOUR SHARES, OR INSTRUCT YOUR
STOCKBROKER TO VOTE THEM FOR YOU, IT WILL HAVE THE SAME EFFECT AS VOTING AGAINST
THE MERGER.
--------------------------------------------------------------------------------
Sincerely,
/s/ Charles E. Bergeron
Charles E. Bergeron
Chief Financial Officer
Epitope Inc.
